Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms
Authors:
- 11 July 2024
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 144 (2) , 137-144
Abstract
Numerous antibody-drug conjugates (ADCs) are being developed for cancer immunotherapy. Although several of these agents have demonstrated considerable clinical efficacy and have won Food and Drug Administration (FDA) approval, in many instances, they have been characterized by adverse side effects (ASEs), which can be quite severe in a fraction of treated patients. The key hypothesis in this perspective is that many of the most serious ASEs associated with the use of ADCs in the treatment of cancer can be most readily explained and understood due to the inappropriate processing of these ADCs via pathways normally followed for immune complex clearance, which include phagocytosis and trogocytosis. We review the key published basic science experiments and clinical observations that support this idea. We propose that it is the interaction of the ADC with Fcγ receptors expressed on off-target cells and tissues that can most readily explain ADC-mediated pathologies, which therefore provides a rationale for the design of protocols to minimize ASEs. We describe measurements that should help identify those patients most likely to experience ASE due to ADC, and we propose readily available treatments as well as therapies under development for other indications that should substantially reduce ASE associated with ADC. Our focus will be on the following FDA-approved ADC for which there are substantial literatures: gemtuzumab ozogamicin and inotuzumab ozogamicin; and trastuzumab emtansine and trastuzumab deruxtecan.Keywords
This publication has 97 references indexed in Scilit:
- Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous ControlsCurrent Protocols, 2023
- Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecanInternational Journal of Clinical Oncology, 2023
- Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response AnalysisThe Journal of Clinical Pharmacology, 2023
- Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic ReviewDrugs, 2022
- Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate AggregatesPharmaceutical Research, 2021
- Neutrophils Kill Antibody-Opsonized Cancer Cells by TrogoptosisCell Reports, 2018
- HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical researchInternational Journal of Cancer, 2016
- Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831Cancer, 2013
- Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptakeCancer Immunology, Immunotherapy, 2012
- Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancerInternational Journal of Clinical Oncology, 2011